Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06163820 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

Study acronym: BETTER
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 13, 2025 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date: Jan 30, 2024 to May 31, 2025 · Study sites: 0 to 1v3 Show 2 more changesShow less
    • Start date: Jan 30, 2024 to May 31, 2025
    • Study sites: 0 to 1
  2. Start date: Dec 1, 2023 to Jan 30, 2024 Primary endpoint revised · Primary and study completion dates: Dec 1, 2025 to Jan 30, 2026v2 Show 2 more changesShow less
    • Primary endpoint revised
    • Primary and study completion dates: Dec 1, 2025 to Jan 30, 2026

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Single arm phase I/II trial to evaluate the safety and efficacy of the combination of bevacizumab, with ipilimumab plus nivolumab, and hypofractionated stereotactic radiotherapy (hSRT) in patients with symptomatic melanoma brain metastases (MBM).
Trial Details
NCT Number NCT06163820
Lead Sponsor Melanoma and Skin Cancer Trials Limited
Conditions Melanoma Brain Metastases
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov